Bilobalide B-sirolimus asymmetric compound drug eluting stent and preparation method thereof

A technology of ginkgolide and sirolimus, applied in the field of medical devices, can solve the problems of unsolved delay in endothelialization, and achieve the effects of promoting rapid endothelialization, good biological stability, and inhibiting restenosis.

Inactive Publication Date: 2015-06-17
SHANGHAI PUTUO DISTRICT CENT HOSPITAL
View PDF3 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Some researchers have used arsenic as the carrier drug of drug-eluting stents, and confirmed that it has good anti-restenotic effect, but its effect is similar to that of sirolimus drug-eluting stent currently on the market, and its endothelialization delay has not yet been resolved

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Bilobalide B-sirolimus asymmetric compound drug eluting stent and preparation method thereof
  • Bilobalide B-sirolimus asymmetric compound drug eluting stent and preparation method thereof
  • Bilobalide B-sirolimus asymmetric compound drug eluting stent and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0025] Example 1 Preparation of ginkgolide B-sirolimus asymmetric composite drug-eluting stent

[0026] Step 1, preparation of coating drug: mix ginkgolide B and polylactic acid at a ratio of 1:1 (mass ratio) to form a "serum" for later use. Mix sirolimus and polylactic acid at a ratio of 1:1 (mass ratio) to form a "slurry" for later use.

[0027] Step 2, apply medicine to the inner and outer surfaces (blood surface) of the asymmetric stent

[0028] The mixture of ginkgolide B and polylactic acid was sprayed on the inner and outer surfaces of the stent by spraying method. According to the calculation by weighing method, each 10mm stent contained 10ug of ginkgolide B on average, and dried at low temperature for storage.

[0029] Step 3, apply medicine to the outer surface of the asymmetric stent (vessel wall)

[0030] Apply the mixture of sirolimus and polylactic acid on the outer surface of the stent (vessel wall) by roller coating method. According to the calculatio...

Embodiment 2

[0031] Example 2 Observation of the physicochemical properties of ginkgolide B-sirolimus asymmetric composite drug-eluting stent

[0032] (1) Detection of coating adhesion of ginkgolide B-sirolimus asymmetric composite drug-eluting stent:

[0033] The developed stent was embedded on the surface of the balloon, and the ginkgolide B-sirolimus asymmetric composite drug-eluting stent was expanded under 12 atmospheres for 12 seconds, and the surface of the stent was uniform and smooth as observed by scanning electron microscopy ( Figure 1a ), under a 100x electronic scanning microscope ( Figure 1b ), the stent showed no significant tearing of the coating, and the coating could be stably applied to the surface of the bare metal stent.

[0034] (2) Detection of coating thickness of ginkgolide B-sirolimus asymmetric composite drug-eluting stent:

[0035] The coating thickness of the stent was measured by a scanning electron microscope, and the coating thickness of the stent was abo...

Embodiment 3

[0041]The preparation method is the same as in Example 1, except that in step 1, ginkgolide B and polylactic acid are mixed at a mass ratio of 1:0.7 to form a "serum" for later use. Mix sirolimus and polylactic acid at a mass ratio of 1:0.7 to form a "slurry" for later use.

[0042] The prepared asymmetric composite drug-eluting stent was tested by the same method as in Example 2, and the results showed that the stent showed no obvious tearing of the coating, and the coating could be stably applied to the surface of the bare metal stent. The degradation rate of polylactic acid of the scaffold reached 90%, and the drug release rate reached 82%.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Thicknessaaaaaaaaaa
Login to view more

Abstract

The invention discloses a bilobalide B-sirolimus asymmetric compound drug eluting stent and a preparation method thereof. A bilobalide B-polylactic acid coating is coated on the inner surface the stent; and a bilobalide B-polylactic acid coating and a sirolimus-polylactic acid coating are sequentially coated on the outer surface of the stent. The preparation method comprises the following steps: 1, mixing bilobalide B with polylactic acid in a mass ratio of 1:(0.7-2) to obtain serous fluid for later use, and mixing sirolimus with polylactic acid in a mass ratio of 1:(0.7-2) to obtain serious fluid for later use; 2, spraying the mixed serous fluid of bilobalide B and polylactic acid to the inner and outer surfaces of the stent, and drying at a low temperature; and 3, roller-coating the mixed serous fluid of sirolimus and polylactic acid to the outer surface of the stent, and drying at a low temperature to obtain the bilobalide B-sirolimus asymmetric compound drug eluting stent. The asymmetric compound drug eluting stent disclosed by the invention has good effects of resisting thrombus, promoting vascular stent endothelialization and resisting restenosis, and can be used as a new-generation coronary medicament stent.

Description

technical field [0001] The invention belongs to the field of medical devices, and relates to a drug-eluting stent, in particular to a ginkgolide B-sirolimus asymmetric composite drug-eluting stent and a preparation method thereof. Background technique [0002] Drug-eluting stents can significantly reduce the incidence of restenosis in coronary intervention, but poor endothelialization of stents and late stent thrombosis are prominent problems in percutaneous coronary intervention. Recent studies have shown that complications such as stent thrombosis, polymer hypersensitivity, stent malapposition, and aneurysm may occur after drug-eluting stent implantation. ) is the most serious complication, which has attracted great attention of scholars at home and abroad. Studies have shown that the main drug-eluting stents in clinical use (such as sirolimus and paclitaxel-eluting stents) have delayed stent endothelialization after implantation in blood vessels, and may be the main caus...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61L31/10A61L31/16A61L31/14A61K31/436A61P7/02A61P9/14A61K31/365
Inventor 郜俊清刘宗军殷佩浩于文陈弢
Owner SHANGHAI PUTUO DISTRICT CENT HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap